Ciclosporin versus infliximab in patients with severe ulcerative colitis refractory to intravenous steroids: a parallel, open-label randomised controlled trial.
about
Elderly patients and inflammatory bowel diseaseImpact of thiopurines and anti-tumour necrosis factor therapy on hospitalisation and long-term surgical outcomes in ulcerative colitisMedical Therapy of Active Ulcerative ColitisAdvances in refractory ulcerative colitis treatment: A new therapeutic target, Annexin A2Review article: applying pharmacokinetics to optimise dosing of anti-TNF biologics in acute severe ulcerative colitisGlucose intolerance and diabetes mellitus in ulcerative colitis: pathogenetic and therapeutic implicationsOptimization of the treatment with immunosuppressants and biologics in inflammatory bowel diseaseReview article: the role of anti-TNF in the management of ulcerative colitis -- past, present and futureTacrolimus for the Treatment of Ulcerative ColitisBiologics in the management of ulcerative colitis - comparative safety and efficacy of TNF-α antagonistsInflammatory pathways of importance for management of inflammatory bowel diseaseRandomised controlled trial. Comparison Of iNfliximab and ciclosporin in STeroid Resistant Ulcerative Colitis: Trial design and protocol (CONSTRUCT)Review article: dose optimisation of infliximab for acute severe ulcerative colitis.Outcomes of rescue therapy in acute severe ulcerative colitis: data from the United Kingdom inflammatory bowel disease audit.Tacrolimus or infliximab for severe ulcerative colitis: short-term and long-term data from a retrospective observational studyBiologics in inflammatory bowel disease: what are the data?Validation of the Crohn's and Ulcerative Colitis questionnaire in patients with acute severe ulcerative colitis.Management of ulcerative colitis in Taiwan: consensus guideline of the Taiwan Society of Inflammatory Bowel Disease.Need for infliximab dose intensification in Crohn's disease and ulcerative colitis.A medicoeconomic review of early intervention with biologic agents in the treatment of inflammatory bowel diseases.Management of acute severe ulcerative colitis.Review article: acute severe ulcerative colitis - evidence-based consensus statements.Current and emerging biologics for ulcerative colitis.Efficacy and Safety of Long-Term Thiopurine Maintenance Treatment in Japanese Patients With Ulcerative ColitisReview article: the practical management of acute severe ulcerative colitis.A Saudi Gastroenterology association position statement on the use of tumor necrosis factor-alfa antagonists for the treatment of inflammatory bowel diseaseInfliximab versus Cyclosporine Treatment for Severe Corticosteroid-Refractory Ulcerative Colitis: A Korean, Retrospective, Single Center Study.MANAGEMENT OF ACUTE SEVERE ULCERATIVE COLITIS: A CLINICAL UPDATE.Protective Effect of Calculus Bovis Sativus on Dextran Sulphate Sodium-Induced Ulcerative Colitis in Mice.First trough level of infliximab at week 2 predicts future outcomes of induction therapy in ulcerative colitis-results from a multicenter prospective randomized controlled trial and its post hoc analysisEfficacy of infliximab in acute severe ulcerative colitis: a single-centre experience.Cost utility of inflammation-targeted therapy for patients with ulcerative colitis.Systematic review and meta-analysis of third-line salvage therapy with infliximab or cyclosporine in severe ulcerative colitis.Qingchang Wenzhong Decoction Ameliorates Dextran Sulphate Sodium-Induced Ulcerative Colitis in Rats by Downregulating the IP10/CXCR3 Axis-Mediated Inflammatory Response.Prognostic factors affecting early colectomy in patients with moderate to severe ulcerative colitis treated with calcineurin inhibitors.Infliximab versus ciclosporin for steroid-resistant acute severe ulcerative colitis (CONSTRUCT): a mixed methods, open-label, pragmatic randomised trialTraditional Chinese medicine combination therapy for patients with steroid-dependent ulcerative colitis: study protocol for a randomized controlled trial.Management of difficult-to-treat patients with ulcerative colitis: focus on adalimumabInvestigational cytokine-targeted therapies for ulcerative colitis.Prolonged preoperative hospital stay is a risk factor for complications after emergency colectomy for severe colitis.
P2860
Q26768270-CB6C7749-F142-45F0-8D14-2017514F5CDDQ26771136-4E4F9739-F9CC-4663-AA40-EF23285C63A0Q26777729-7A3FD235-5665-4377-AF83-B18E52873A33Q26798299-63077B2C-EB59-4B09-9764-253E0B88FD68Q26823221-2A97BC3E-2D71-4925-A28C-F8071650D1D8Q26866110-10C194BE-65B0-4BDD-A370-AB6E5EE20BCEQ26866940-66B2B73F-D7B3-4F08-BD93-F393F86180A8Q26992012-8C73BEA0-77B5-49CE-9C88-737E9232350AQ26997361-8363436D-7D37-4222-8DCF-461BA243BFBEQ26999078-DD98F089-4BBD-435B-80DF-DA53FEBEEBF6Q27005445-A874B835-D939-4446-8FD1-54F9707B1D7BQ28657925-E7AADCC7-C746-44A5-8E88-DF0DF9AAB94EQ30239077-0A712865-ADD6-480B-A969-D54A1D6AE2E6Q30664895-80373230-FBB9-4CFD-8C92-87ADEB610DABQ31004717-0DF9A4A7-BB73-4663-9AA4-23DA17805391Q31017419-B1705803-AA22-4E50-8FA9-A9EAFBA38745Q33732010-DF312F51-BFCC-40CC-8960-77172CBFDB9DQ33819473-C9C8DDF3-8F93-4155-BED2-15959E6E7991Q33958740-26B53F20-52C4-4845-B60C-C03F3B4D415BQ34353032-3607EEC4-8B4B-4EEB-9D9D-25A614A574A7Q34508900-F812A0F1-152D-41C7-946A-61524459ED82Q34528270-B48F63C5-01F5-4DBD-8F63-102A6B0E41B8Q34809305-08E1CF7A-131C-47CC-ADFA-7BB04B728C53Q35777883-2CA6000B-4229-436C-A942-15DF335AC024Q35883580-7E191B6A-ECAD-4BE5-999F-40C1F40C75B3Q35973766-4C8D0FF1-C32F-45EB-91CA-FC88A0407268Q36037115-A7B43D69-0231-499A-9437-2B8C5A48FBC5Q36167512-8F78CF60-C6B1-411E-99B6-6777A2CE9C58Q36249551-A9D83367-1CF4-42E0-B2BF-03344BC96ADEQ36615081-A1C229B3-748A-47A1-AD0B-0B3B092F16B6Q36637710-FE304124-B169-4695-AFB8-BC983341A7BCQ36815176-3D9CAFF0-40EC-4502-9219-3668BF939F47Q37044321-FE4A8E60-B45A-421F-A7A7-8266DA014920Q37054120-218526FF-FE06-4E76-96D8-6EA3CDC22236Q37106707-4F383D81-E571-4D57-963E-CD16F90C594EQ37196938-9C0E9A6A-84C8-4495-89A9-8BB3311DA8EEQ37576428-E0EDE4DA-7E71-461F-AECC-1CCF4A800BF6Q38102982-963B3F80-172F-4CE1-9EDF-2C0E73F4C093Q38117175-DA485E4C-5294-48F8-A964-CC4794ADE9B6Q38117907-AF5E1ADB-1BF4-4B44-9958-1179087A0708
P2860
Ciclosporin versus infliximab in patients with severe ulcerative colitis refractory to intravenous steroids: a parallel, open-label randomised controlled trial.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh
2012年學術文章
@zh-hant
name
Ciclosporin versus infliximab ...... l randomised controlled trial.
@en
Ciclosporin versus infliximab ...... l randomised controlled trial.
@nl
type
label
Ciclosporin versus infliximab ...... l randomised controlled trial.
@en
Ciclosporin versus infliximab ...... l randomised controlled trial.
@nl
prefLabel
Ciclosporin versus infliximab ...... l randomised controlled trial.
@en
Ciclosporin versus infliximab ...... l randomised controlled trial.
@nl
P2093
P50
P1433
P1476
Ciclosporin versus infliximab ...... l randomised controlled trial.
@en
P2093
Antonio Lopez-Sanroman
Arnaud Bourreille
Benoit Coffin
David Laharie
Denis Franchimont
Elena Ricart
Franck Carbonnel
Frank Zerbib
Gilles Bommelaer
Groupe d'Etudes Thérapeutiques des Affections Inflammatoires Digestives
P304
P356
10.1016/S0140-6736(12)61084-8
P407
P577
2012-10-10T00:00:00Z